Biopolym. Cell. 2023; 39(1):54-59.
http://dx.doi.org/10.7124/bc.000A8A
Discussions
New antimicrobial properties of “old” 5-fluorouracil
1Pletnova L. V., 1Volynets G. P., 1Kachaput N. O., 1Maiula T. H., 1Tverdyi D. O., 1Koshman O. O., 1, 2Matiushok V. I., 1Bdzhola V. G., 1Yarmoluk S. M.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03143
  2. LLC "Scientific and service firm "Otava"
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03143

Abstract

Aim. The objective of this study was to determine the activity of 5-fluorouracil (5-FU) against five pathogenic bacteria: Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 700603, Acinetobacter baumannii ATCC 19606, Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 433 and two fungi: Candida albicans ATCC 90028 and Cryptococcus neoformans ATCC 208821. Methods. 5-FU was tested by broth microdilution against selected microorganisms. Results. It was found that 5-FU significantly inhibits growth of S. aureus ATCC 43300 and C. neoformans ATCC 208821 (MIC <= 0.25 mg/L). P. aeruginosa ATCC27853, K. pneumonia ATCC 700603 and C. albicans ATCC90028 were considered to be resistant to 5-FU (MIC > 32mg/L) and A. baumanii ATCC 19606 and E. coli ATCC 25922 were considered to be intermediate (MIC = 16mg/L). Conclusions. These findings suggest that 5-FU could be promising drug candidate for the treatment of infection diseases caused by methicillin-resistant S. aureus (MRSA) ATCC 43300 and C. neoformans ATCC 208821.
Keywords: 5-fluorouracil, antibacterial activity, antifungal activity
Full text: (PDF, in English)

References

[1] More LA, Lane S, Asnani A. 5-FU cardiotoxicity: vasospasm, myocarditis, and sudden death. Curr Cardiol Rep. 2021; 23(3):17.
[2] Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, Herrmann J, Lerman A, Grothey A. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018; 10:1758835918780140.
[3] Christensen S, Van der Roest B, Besselink N, Janssen R, Boymans S, Martens JWM, Yaspo ML, Priestley P, Kuijk E, Cuppen E, Van Hoeck A. 5-Fluorouracil treatment induces characteristic T>G mutations in human cancer. Nat Commun. 2019; 10(1):4571.
[4] Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000; 18(4):299-313.
[5] Huczyński A, Antoszczak M, Kleczewska N, Lewandowska M, Maj E, Stefańska J, Wietrzyk J, Janczak J, Celewicz L. Synthesis and biological activity of salinomycin conjugates with floxuridine. Eur J Med Chem. 2015; 93:33-41.
[6] Steinfeld AS, Naider F, Becker JM. Anticandidal activity of 5-fluorocytosine-peptide conjugates. J Med Chem. 1979; 22(9):1104-9.
[7] Kingsbury WD, Boehm JC, Mehta RJ, Grappel SF, Gilvarg C. A novel peptide delivery system involving peptidase activated prodrugs as antimicrobial agents. Synthesis and biological activity of peptidyl derivatives of 5-fluorouracil. J Med Chem. 1984; 27(11):1447-51.
[8] Schwarz P, Janbon G, Dromer F, Lortholary O, Dannaoui E. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob Agents Chemother. 2007; 51(1):383-5.
[9] Yasumoto M, Moriyama A, Unemi N, Hashimoto S, Suzue T. Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers. J Med Chem. 1977; 20(12):1592-4.
[10] Imperi F, Fiscarelli EV, Visaggio D, Leoni L, Visca P. Activity and impact on resistance development of two antivirulence fluoropyrimidine drugs in Pseudomonas aeruginosa. Front Cell Infect Microbiol. 2019; 9:49.
[11] Di Bonaventura G, Lupetti V, De Fabritiis S, Piccirilli A, Porreca A, Di Nicola M, Pompilio A. Giving drugs a second chance: antibacterial and antibiofilm effects of ciclopirox and ribavirin against cystic fibrosis Pseudomonas aeruginosa strains. Int J Mol Sci. 2022; 23(9):5029.
[12] Duschinsky R, Pleven E, Heidelberger C. The synthesis of 5-fluoropyrimidines. J. Am. Chem Soc. 1957; 79(16), 4559-60.
[13] Barton DH, Hesse RH, To HT, Pechet MM. A convenient synthesis of 5-fluorouracil. J Org Chem. 1972; 37(2):329-30.
[14] Iglewicz B, Hoaglin D. (1993), Vol. 16: How to Detect and Handle Outliers", The ASQC Basic References in Quality Control: Statistical Techniques, Edward F. Mykytka, Ph.D., Editor.
[15] Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol. 2014; 11(5):282-98.
[16] Oe C, Hayashi H, Hirata K, Kawaji K, Hashima F, Sasano M, Furuichi M, Usui E, Katsumi M, Suzuki Y, Nakajima C, Kaku M, Kodama EN. Pyrimidine analogues as a new class of gram-positive antibiotics, mainly targeting thymineless-death related proteins. ACS Infect Dis. 2020; 6(6):1490-500.
[17] Ahmad SI, Kirk SH, Eisenstark A. Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annu Rev Microbiol. 1998; 52:591-625.
[18] Ueda A, Attila C, Whiteley M, Wood TK. Uracil influences quorum sensing and biofilm formation in Pseudomonas aeruginosa and fluorouracil is an antagonist. Microb Biotechnol. 2009; 2(1):62-74.
[19] Blaskovich MA, Zuegg J, Elliott AG, Cooper MA. Helping chemists discover new antibiotics. ACS Infect Dis. 2015; 1(7):285-7.